Diagnostics winner; sees revenue spikes from testing scales before vaccine rollout.

The stock was down after announcing its acquisition of Exact Sciences, indicating a negative market reaction to the deal.

The combination of corporate lobbying for the 'Circuit Act' and recent stock purchases by multiple bipartisan members of Congress presents a potentially bullish case for the stock.

Removed from the GRNY ETF portfolio during its August 2025 rebalance.

The FDA commissioner's positive mention of wearable glucometers is a bullish signal for Abbott, which makes the FreeStyle Libre, and suggests an expanding market beyond just diabetes management.

Bullish view due to strong growth in its diabetes (Freestyle) and medical devices businesses, which are described as being 'on fire' and offsetting weakness in other segments.